Literature DB >> 32583529

Effect of reoxygenation on hypofractionated radiotherapy of prostate cancer.

V Y Kuperman1, L M Lubich2.   

Abstract

PURPOSE: To assess the role of reoxygenation of hypoxic tumor cells in hypofractionated radiotherapy of prostate cancer.
METHODS: The considered radiobiological model is based on the assumption of two populations (compartments) of cells: oxygenated (aerobic) cells and hypoxic cells. After each fraction of radiation, some of the hypoxic cells reoxygenate while a fraction of initially aerobic cells becomes hypoxic. The kinetics of this process between successive treatments is described by coupled, first-order differential equations. To determine the effect of reoxygenation on cell kill in the treatment target, we utilize the linear-quadratic (LQ) model assuming different radiosensitivities for the aerobic and hypoxic cells.
RESULTS: Analytical solutions for the number of surviving malignant cells are obtained for special cases of slow and fast reoxygenation. The radiobiological effect of reoxygenation for different fractionation regimens is also evaluated numerically.
CONCLUSIONS: In this study, a radiobiological model for kinetics of reoxygenation in tumors is used to evaluate different fractionation schedules in radiotherapy of prostate cancer. The obtained results indicate that in the case of low alpha/beta ratio for malignant cells (e.g., α / β  = 1.5 Gy), treatment schedule with 4-10 fractions and dose per fraction >4-5 Gy can result in increased cell kill in the treatment target at the same level of rectal toxicity as compared to conventional fractionation. The findings of this study also suggest that radiotherapy of the prostate with 1-3 fractions can be radiobiologically inferior to treatments with greater number of fractions.
© 2020 American Association of Physicists in Medicine.

Entities:  

Keywords:  hypofractionation; prostate; radiotherapy; reoxygenation

Mesh:

Year:  2020        PMID: 32583529     DOI: 10.1002/mp.14343

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  2 in total

Review 1.  The evolution of rectal cancer treatment: the journey to total neoadjuvant therapy and organ preservation.

Authors:  Arthur Affleck Iv; Marina Affi Koprowski; Nima Nabavizadeh; Vassiliki Liana Tsikitis
Journal:  Ann Gastroenterol       Date:  2022-04-07

2.  Technical Note: Break-even dose level for hypofractionated treatment schedules.

Authors:  Till Tobias Böhlen; Jean-François Germond; Jean Bourhis; Marie-Catherine Vozenin; Claude Bailat; François Bochud; Raphaël Moeckli
Journal:  Med Phys       Date:  2021-10-22       Impact factor: 4.506

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.